Sionna Therapeutics advancing SION-451 + SION-2222 into Phase 2 trial in Q1 2027
Sionna Therapeutics announced it will initiate a Phase 2 proof-of-concept trial for the combination of SION-451 and SION-2222 in late 2026, maintaining a strong cash position to support operations into 2029 despite discontinuing SION-719.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed